Theoretically, providing docetaxel for metastatic estrogen receptor-positive breast cancer when the ovary is in the follicular phase of the menstrual cycle [36] when estradiol approaches peak levels, likely at 10–14 days from the beginning of the menstrual cycle, could be more potent than providing it during other parts of the cycle. The gene discussed is ESR1; the disease is breast carcinoma.